The Conversation (0)
Tetra Bio-Pharma announced a bought deal financing agreement worth 8,000,000 units gross proceeds of approximately $8 million.
Tetra Bio-Pharma (TSXV:TBP; OTCQB:TBPMF) announced a bought deal financing agreement worth 8,000,000 units gross proceeds of approximately $8 million.
As quoted in the press release:
Each Unit will consist of one common share (a “Common Share”) in the Company and one warrant (a “Warrant” and collectively the “Warrants”). Each Warrant will entitle the holder thereof to acquire one Common Share at a price of $1.30, for a period of 36 months from the Closing Date.
“We are extremely pleased to partner with Echelon Wealth Partners in securing this financing agreement. As we are about to initiate our Health Canada’s recently approved phase 3 registration trial for our lead drug candidate, PPP001, in late stage cancer patients, the proceeds from this Offering will enable Tetra to continue, and even accelerate some of the key development projects in our pipeline. This is another milestone in working towards becoming the first biopharmaceutical company in the world to get a smokable dried cannabis product approved as a prescription drug by Health Canada, the FDA and other regulatory agencies around the world,” states Bernard Fortier, CEO of Tetra Bio-Pharma.
The Company intends to use the net proceeds of the Offering to advance the Company’s Phase 3 trial for PPP001 and other clinical trials, to effect the repayment of indebtedness and for general corporate and working capital purposes.
Click here to read the full press release.
Source: web.tmxmoney.com
